Author: Ravi Shankar

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award

DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently no FDA-approved pharmacologic treatment

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced the issuance of U.S. Patent No. 12,678,439, titled “Lopinavir and Ritonavir for the Treatment of Cervix Disorders,” which covers pharmaceutical compositions formulated for topical application comprising lopinavir and ritonavir for the treatment of HPV-related cervical pathologies.

The patent, issued by the United States Patent and Trademark Office on July 14, 2026, to Douglas Pharmaceuticals Limited, a licensor to Daré Bioscience, describes pharmaceutical compositions containing therapeutically effective amounts of lopinavir and ritonavir, including specific lopinavir-to-ritonavir weight ratios and formulations designed for topical administration. The patent includes claims directed to compositions for treating or inhibiting the development of early-stage neoplasias and for treating or preventing HPV-related cervical neoplasias. The patent is expected to provide protection into at least 2039.

“This patent adds another important layer to the foundation we are building around DARE-HPV at a particularly exciting point in the program’s development,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Millions of women experience high-risk HPV infection each year in the United States, yet there is still no FDA-approved pharmacologic treatment to clear the infection. DARE-HPV is designed to change that paradigm with a localized, self-administered, non-surgical approach, and our Phase 2 study is now evaluating its potential to do exactly that. With clinical development underway, significant non-dilutive funding supporting the program, and an expanded intellectual property position, we believe DARE-HPV represents a compelling opportunity to address a significant unmet need in women’s health and, if successful and approved, potentially establishing the first FDA-approved pharmacologic treatment for HPV infection.”

The patent adds to the intellectual property landscape supporting the development of DARE-HPV, Daré Bioscience’s investigational proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert being developed as a potential treatment for persistent high-risk human papillomavirus (HPV) infection. Daré holds an exclusive U.S. license to the patent described above and the broader patent family related to DARE-HPV under its 2023 license agreement with Douglas Pharmaceuticals Limited.

DARE-HPV is currently being evaluated in a Phase 2 randomized, placebo-controlled, double-blind clinical study in approximately 100 women with confirmed persistent high-risk HPV infection (ClinicalTrials.gov ID: NCT07601074). The study is designed to evaluate the safety and antiviral activity of lower and higher doses of DARE-HPV compared with placebo over an up to 21-day course of daily treatment, with HPV clearance at three months post-treatment as the primary endpoint. Topline results are expected in 2027.

DARE-HPV is being developed as a non-surgical, localized, self-administered therapy designed to clear persistent high-risk HPV infection. There are currently no FDA-approved pharmacologic treatments for HPV infection. Daré Bioscience’s development of DARE-HPV is supported by approximately $10 million in non-dilutive funding from the Advanced Research Projects Agency for Health (ARPA-H) as Sprint for Women’s Health awardee, and a $2.0 million award granted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (Award Number R44AI188623).

ABOUT DARE-HPV

DARE-HPV is an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert being developed as a potential non-surgical, localized, self-administered treatment for persistent high-risk HPV infection. Lopinavir and ritonavir are protease inhibitors with established antiviral activity. HPV infection is the underlying cause of virtually all cervical cancer cases in the United States. An estimated six million women per year in the United States experience high-risk HPV infection, for which there are currently no FDA-approved pharmacologic treatments. If clinically successful and approved, DARE-HPV could be the first FDA-approved pharmacologic treatment for HPV infection.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-HPV’s potential as a safe and effective treatment for clearance of high-risk HPV infection; DARE-HPV’s potential to be a first-in-category treatment targeting persistent high-risk HPV infection and to be the first FDA-approved pharmacologic treatment for high-risk HPV infection; the conduct and completion of the Phase 2 clinical study of DARE-HPV and the timing of topline data from the study; the anticipated benefits of DARE-HPV, including its potential to reduce the incidence of cervical cancer in the U.S.; the potential for DARE-HPV to redefine the treatment paradigm in cervical disease prevention; the expected duration of patent protection into at least 2039; Daré Bioscience’s expectation of receipt of additional funding under its ARPA-H award and NIAID award; and the potential market opportunity for DARE-HPV, if approved. As used in this press release, “first-in-category” is a forward-looking statement relating to the potential of a product candidate to represent a new category of product if it were to receive marketing approval for the indication for which it is being developed because Daré Bioscience believes it would address a need in women’s health that is not being met by existing FDA-approved products.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: failure or delay in conducting or completing clinical trials and the inherent uncertainty of outcomes of clinical trials; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; Daré Bioscience’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; the risk that Daré Bioscience’s product candidates may fail to demonstrate acceptable safety and tolerability or sufficient efficacy in clinical trials; Daré Bioscience’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré Bioscience’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the potential that a product candidate in clinical development may never advance into or through a pivotal clinical study or obtain FDA or foreign regulatory approval; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré Bioscience’s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré Bioscience anticipates, or that the duration of a study or number of study subjects must be significantly greater than anticipated; Daré Bioscience’s ability to achieve the milestones required for it to receive additional payments under its ARPA-H award and NIAID award; Daré Bioscience’s dependence on grants and other financial awards from governmental entities and the risk that funding may be reduced, delayed, or terminated; Daré Bioscience’s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Daré Bioscience’s ability to maintain compliance with Nasdaq’s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience’s ability to raise additional capital or on Daré Bioscience’s operations, financial results and condition, and ability to achieve current plans and objectives; the risk that the intellectual property landscape supporting DARE-HPV, including the newly issued patent and the licensed patent family, may not provide the expected scope or duration of protection, and the risk that patent protection may not extend into 2039 as currently expected; the risk that the current regulatory pathway known as the FDA’s 505(b)(2) pathway for drug product approval in the U.S. is not available for a product candidate as Daré Bioscience anticipates; the risk that developments by competitors make Daré Bioscience’s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré Bioscience’s products or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Daré Bioscience’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience’s product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience’s products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; and cybersecurity incidents or similar events that compromise Daré Bioscience’s technology systems and/or significantly disrupt Daré Bioscience’s business or those of third parties on which Daré Bioscience relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com 
Source: Daré Bioscience, Inc.

Borregaard has today entered into three bilateral multicurrency revolving credit facility agreements with Danske Bank, DNB Bank ASA, and Skandinaviska Enskilda Banken, respectively. The facilities, which are linked to sustainability targets, amount in total to NOK 1,500 million, with each bank providing NOK 500 million.

The margin under the respective facilities can be adjusted based on Borregaard’s progress on three parameters: (i) the Group’s target of reducing greenhouse gas emissions (Scope 1 and 2), (ii) reduction of the Group’s total recordable injuries and (iii) reduced emissions of organic compounds to the Glomma river.

The facilities have tenors of five years with two one-year extension options. The new facilities are for general corporate purposes and replace the NOK 1,500 million revolving credit facilities with maturity in 2027.

Skandinaviska Enskilda Banken acted as documentation coordinator for the facilities.

Borregaard ASA,
Sarpsborg, 28 September 2026

Contact:
Group Treasurer and IR, Magnus Hammerstad, +47 959 04 640

This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act and requirements under the EU Market Abuse Regulation.

Enters into a non-binding term sheet which will potentially provide control over two data center development projects in Warsaw and Wroclaw, Poland, with planned capacity of up to 270 MW

NESS ZIONA, Israel, Sept. 28, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced today that it has entered into a non-binding term sheet for the proposed acquisition of a 50.01% controlling interest in a company advancing data center development projects in Poland (the “Data Centers Company”).

The Data Centers Company is expected to hold a 66.67% interest in each of two Polish project companies developing data centers in Warsaw and Wroclaw, two of the biggest and growing cities in Poland. The Warsaw project has a planned power capacity of 130 MW, while the Wroclaw project has a planned capacity of up to 140 MW, representing combined planned capacity of up to 270 MW.

The remaining 33.33% interest in both projects will be held by Polish development entrepreneurs who are engineering experts leading national grid connection processes, techno-economic analysis and regulatory matters and lead the securing of grid connection terms for projects totaling several gigawatts.

The Warsaw project, located in Ożarów, Poland, includes approximately 3.2 hectares of secured land, with an additional 2.2-hectare option. A grid connection application has been submitted, with final permit currently expected by the end of 2027. The Wroclaw project encompasses approximately 10 hectares, with its feasibility study completed and land currently under negotiation.

According to the data produced by the European Data Centre Association , Poland’s colocation capacity is forecast to increase from approximately 29 MW in 2026 to 511 MW by 2031, underscoring the country’s position as a growing data center market in the Central and Eastern Europe.

Haim Siboni, Chief Executive Officer of Foresight, said, “As we previously announced, Foresight has been evaluating opportunities to expand into new technology markets and identify additional areas for growth beyond our existing activities, including data centers. The proposed transaction is a natural extension of this strategy, providing Foresight with an opportunity to establish a controlling interest in a platform advancing two data center projects in Poland. At the same time, we continue to advance our proprietary technologies and expand their applications, including our recently announced development of full autonomous driving solutions for Unmanned Ground and Aerial Vehicles.”

The purchase price for the 50.01% interest in the Data Centers Company will be determined based on an independent valuation to be prepared by a mutually agreed independent valuation firm prior to execution of definitive agreements. The consideration would be financed in full through a seller loan.

At closing, Foresight expects to also contribute an amount currently estimated at approximately $1 million, representing its pro rata share of the Data Centers Company’s outstanding shareholder loans, and would commit to provide additional shareholder loans of up to $2.5 million to advance the two projects. To fund these obligations, the Data Centers Company current shareholders, or anyone on their behalf, shall provide Foresight with a convertible loan facility, from time to time, of up to US$3,500,000, all subject to an agreed budget, business plan and projects milestones, with terms to be agreed upon a separate agreement.

The proposed transaction remains subject to the completion of Foresight’s due diligence, an independent valuation, agreement on definitive transaction documents and transaction structure, and receipt of required corporate, regulatory, stock exchange, governmental, financing, and third-party approvals.

Eli Yoresh, the Company’s Chief Financial Officer, owns a 10% stake in the Data Centers Company.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional (3D) perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd., and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.

Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment, and unmanned aerial vehicles (UAVs).

Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on X, or join Foresight Automotive on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the likelihood of success of data center development in Poland, possible growth in the European energy market, the likelihood of energy production by the potential data centers, entry into definitive agreements and future cooperation between the parties to the nonbinding term sheet and that the proposed transaction remains subject to the completion of Foresight’s due diligence, an independent valuation, agreement on definitive transaction documents and transaction structure, and receipt of required corporate, regulatory, stock exchange, governmental, financing, and third-party approvals. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the content of third party websites.

Investor Relations Contact:
Miri Segal-Scharia
CEO
MS-IR LLC
msegal@ms-ir.com

        
– Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib

– New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships

TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—
today announced that it has expanded the capabilities of its in-house medical laboratory to include proteomics and cell line research.

The new capabilities build on the laboratory’s existing transcriptomics research and CLIA clinical testing services and are expected to support Allarity in several areas. Internally, the expanded capabilities will allow the Company to conduct additional research into the mechanism of action of its lead asset, stenoparib. Externally, these capabilities broaden the range of research projects and laboratory services that Allarity can offer to existing and prospective customers.

Proteomics has become an increasingly important component of translational cancer research by providing information about protein expression, signaling pathways and the molecular mechanisms involved in tumor growth, progression and treatment response. Integrating proteomic analysis with transcriptomic and cell-based research can provide a more comprehensive view of tumor biology and help identify therapeutic targets and modulators of drug response.

“By combining transcriptomics, proteomics and cell line research within our own laboratory infrastructure, we can generate a broader set of molecular insights to support our stenoparib development program. We expect this to be particularly valuable as we continue to deepen our dialogue with leading oncologists and other stakeholders, both to better understand stenoparib’s differentiated mechanism of action and to further sharpen our understanding of the cancer indications in which it may have the greatest potential,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “At the same time, these expanded capabilities allow us to broaden the scientific services we can provide to external partners.”

Allarity’s medical laboratory is equipped with an nCounter® Pro instrument that supports the Company’s transcriptomics research and CLIA clinical services. The platform can now also be applied to proteomics research using the nCounter® Human Tumor Signaling Protein Panel, which measures approximately 300 protein targets. Together with the addition of cell line research capabilities, this significantly expands the range of molecular and preclinical research that Allarity can conduct in-house.

The expanded laboratory capabilities will not affect the Company’s current cash runway. Rather, these may generate significant cost efficiencies by enabling more research activities to be conducted in-house.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

Allarity has completed its first Phase 2 trial evaluating stenoparib in patients with advanced ovarian cancer. The trial demonstrated promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from the trial were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The amended protocol enrolls only platinum-resistant or platinum-ineligible patients and is designed to advance the clinical development of stenoparib toward potential FDA approval.

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated benefits of the Company’s expanded laboratory capabilities, including the use of proteomics and cell line research to support mechanism-of-action studies for stenoparib; the potential for these capabilities to generate additional molecular insights; and the Company’s ability to broaden the research and laboratory services offered to existing and prospective external partners. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully implement and utilize its expanded proteomics and cell line research capabilities; the possibility that these capabilities may not generate the anticipated scientific insights or support the development of stenoparib as expected; operational, technical, regulatory or quality-related challenges associated with laboratory service delivery; the Company’s ability to attract and retain external customers for its expanded laboratory services; and the Company’s overall financial resources. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###

Company Contact:
     investorrelations@allarity.com
        
Media Contact:
     Thomas Pedersen
     Carrotize PR & Communications
     +45 6062 9390
     tsp@carrotize.com

Attachment

• Allarity Therapeutics Expands Laboratory Capabilities

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date	Total repurchased shares	Weighted average price	Total repurchased value
21-Sep-26	25,500	€1,479.91	€37,737,595
22-Sep-26	29,000	€1,492.35	€43,278,199
23-Sep-26	43,000	€1,510.06	€64,932,593
24-Sep-26	57,700	€1,505.71	€86,879,282
25-Sep-26	10,000	€1,533.55	€15,335,519

ASML’s current share buyback program was announced on 28 January 2026. Further details are available on our website.

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

Media Relations contacts Monique Mols, phone +31 6 528 444 18

Investor Relations contacts Jim Kavanagh, phone +31 40 268 3938 Pete Convertito, phone +1 203 919 1714 Peter Cheang, phone +886 3 659 6771

        

Recognition honors Kaltura’s Agentic Avatars for turning static content into real-time, guided conversations, resulting in substantial improvements in audience

New York, New York, Sept. 28, 2026 (GLOBE NEWSWIRE) — Kaltura (Nasdaq: KLTR), the Agentic Digital Experience company, today announced that it has won Best Interactive Content Platform in the 2026 Digiday Technology Awards for the Kaltura Agentic Avatars. The Digiday Technology Awards recognize companies embracing AI and automation tools to enhance personalized experiences, enable precise targeting and drive performance across platforms and channels. 

Kaltura’s Agentic Avatars turns an organization’s own video and knowledge into live, conversational, agentic experiences that do more than answer a question. It builds the experience around the answer, assembling video clips, text, charts, and event details into a layout shaped by the conversation and by what it already knows about the person, grounded in verified, on-brand knowledge and available across languages, around the clock. 

The results are measurable. Across Kaltura deployments, Agentic Avatars have driven substantial increases in both audience engagement and the number of sales-qualified leads, while lowering live support costs by handling first-line guidance and escalating only the conversations that need a human. 

“The way people engage with information is changing faster than it has in decades. Static pages and endless search are giving way to intelligent, conversational experiences that understand what someone needs and respond in the moment,” said Ron Yekutiel, Co-Founder, Chairman, President and Chief Executive Officer of Kaltura. “Agentic Avatars are how enterprises make that shift, turning their knowledge into experiences that see, listen, guide, and act on behalf of the people they serve. We believe the future of digital experience is agentic, and being named Best Interactive Content Platform by Digiday tells us the market agrees .” 

The recognition follows a year of continued expansion of Kaltura’s AI portfolio, including its Avatar Video Production Studio, Avatar-Powered Roleplay for enterprise learning and training, and advances in real-time emotional intelligence for Agentic Avatars. Kaltura and PathFactory, a Kaltura company, have also received recent recognition from Gartner, Forrester, IDC, ISG Research, Frost & Sullivan and Aragon Research across conversational AI, enterprise video, virtual events and related digital experience markets. 

About Kaltura 

Kaltura’s mission is to power rich, agentic digital experiences across organizational journeys for customers, employees, learners, and audiences. Its platform combines intelligent content creation, enterprise-grade content management and intelligence, and multimodal conversational engagement capabilities. Kaltura serves leading enterprises, financial institutions, educational institutions, media and telecom providers, and other organizations worldwide. For more information, visit www.kaltura.com.  

CONTACT: Nohar Zmora 

SVP, Head of Marketing 

pr.team@kaltura.com 

 

The recognition highlights Paychex’s financial strength, innovation, and sustainability

• Paychex earned 5-out-of-5-stars on Newsweek’s America’s Greatest Companies 2026 list
• The recognition evaluates companies across four pillars: financial strength, market performance as an American employer, innovation, and environmental sustainability

ROCHESTER, N.Y., Sept. 28, 2026 (GLOBE NEWSWIRE) — Paychex (Nasdaq: PAYX), a leading provider of expert-enabled HR, payroll, and benefits, today announced it has been named to Newsweek’s America’s Greatest Companies 2026, earning a 5-out-of-5-star rating on the national list.

Recognized Across Every Pillar of Performance
The recognition reflects the strength of Paychex’s business across every dimension that Newsweek and Plant-A Insights Group measure. The America’s Greatest Companies ranking evaluates U.S.-based, publicly traded companies on four pillars: financial strength, market performance as an American employer, innovation, and environmental sustainability.

“This recognition reflects the strength of Paychex and our commitment to delivering long-term value for all our stakeholders,” said John Gibson, Paychex president and CEO. “Our financial performance, dedicated employees, responsible business practices, and culture of innovation all contribute to our success. AI is accelerating what is possible, and we are investing in it thoughtfully to enhance our solutions, empower our teams, and ultimately deliver on our purpose of helping businesses succeed.”

Demonstrated Commitment to AI and Innovation
The national recognition comes as Paychex scales WISE (Workforce Intelligence Strengthened by Expertise), its AI-powered intelligence engine embedded across its HCM platforms – Paychex Flex®, Paycor®, and SurePayroll. Early results from more than 50,000 businesses using WISE show it is helping customers catch approximately 90% of payroll errors before they happen and resolve service requests faster.

A Proven Track Record of Recognition
Earlier this year, Paychex was named to Human Resource Executive’s Top HR Products of the Year, Newsweek’s Most Trustworthy Companies in America, and Ethisphere’s World’s Most Ethical Companies list for the 18th time.

To learn more about Paychex’s awards and honors, visit the awards page.

About Paychex
Paychex, Inc. (Nasdaq: PAYX) provides a comprehensive suite of expert-enabled technology and advisory solutions that help businesses manage HR, payroll, and benefits. Serving approximately 840,000 customers and paying 1 in 11 U.S. private sector workers, Paychex combines scale, trusted expertise, and innovation to help businesses succeed. Built on more than 50 years of workforce experience and one of the industry’s largest proprietary HR datasets, Paychex’s WISE agentic AI engine embeds intelligence directly into workflows to improve productivity, enhance decision-making, and deliver better outcomes. Learn more at paychex.com.

Media Contact
Tracy Volkmann
Paychex, Inc.
Manager, Public Relations
(585) 387-6705
tvolkmann@paychex.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c0b0009-8f4b-4585-91b3-e7ac800bb28c

Study advances development of Lantheus’ investigational GRPR-targeted PET imaging program for prostate cancer

BEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the first patient has been dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial evaluating LNTH-2401 (⁶⁸Ga-DOTA-RM2). LNTH-2401 is an investigational gallium-68-labeled positron emission tomography (PET) imaging agent that targets the gastrin-releasing peptide receptor (GRPR), a biomarker that is highly expressed in many prostate cancers.

SPARROW is an open-label, non-randomized, multicenter Phase 2/3 study that includes an initial Phase 2 dose optimization period followed by a Phase 3 diagnostic performance period. The Phase 3 co-primary endpoints are sensitivity and specificity of LNTH-2401 PET/CT imaging compared with histopathology. The Phase 3 portion of the trial is expected to enroll approximately 400 participants and will evaluate diagnostic performance, safety and tolerability.

“Accurate characterization of disease remains critically important in prostate cancer, particularly as treatment decisions become increasingly personalized,” said Harshad R. Kulkarni, MD, Chief Medical Advisor at BAMF Health and a principal investigator in the SPARROW study. “We are pleased to have dosed the first patient at BAMF Health, where our integrated molecular imaging, radiopharmacy and clinical trials infrastructure supports the evaluation of emerging radiopharmaceutical technologies. GRPR represents a promising and biologically distinct target in prostate cancer, and SPARROW will help define the role GRPR-targeted PET may play in disease detection and characterization.”

GRPR is highly expressed in many primary prostate cancers and has a biologic expression pattern distinct from PSMA. Emerging research suggests GRPR-targeted imaging may provide additional insight in certain tumors that are not optimally characterized using PSMA-directed approaches alone.¹

“Dosing the first patient in SPARROW represents a significant step forward for our pipeline and underscores our commitment to advancing innovative radiopharmaceuticals across the prostate cancer care continuum,” said Ludger Dinkelborg, Head of Research and Development at Lantheus. “As the leader in prostate cancer PSMA PET imaging, LNTH-2401 has the potential to expand our understanding of prostate cancer biology through a complementary imaging target. This program reflects our broader strategy to build a focused pipeline of differentiated radiodiagnostics that may support more informed clinical decision-making.”

About SPARROW
SPARROW is an open-label, non-randomized, multicenter Phase 2/3 clinical trial evaluating investigational 68Ga-LNTH-2401 PET/CT imaging in prostate cancer. The study consists of a Phase 2 dose optimization period followed by a Phase 3 diagnostic performance period.

During Phase 2, up to 12 imaging-evaluable participants with newly diagnosed or biochemically recurrent prostate cancer will receive 68Ga-LNTH-2401 PET/CT imaging to determine the optimal administered activity and imaging time window. Phase 2 will also assess biodistribution, radiation dosimetry, image quality, safety and tolerability. Data from participants with GRPR-positive lesions are expected to support selection of the administered activity and imaging time window for Phase 3.

During Phase 3, approximately 400 participants with newly diagnosed prostate cancer who are at least high risk or have suspected metastatic disease and are eligible for radical prostatectomy with pelvic lymph node dissection will undergo 68Ga-LNTH-2401 PET/CT imaging using the optimized imaging parameters selected during Phase 2.

The Phase 3 co-primary endpoints are participant-level sensitivity and specificity of 68Ga-LNTH-2401 PET/CT imaging compared with histopathology. Secondary diagnostic performance assessments include positive predictive value (PPV), negative predictive value (NPV), regional detection performance, comparative summaries versus conventional imaging and/or PSMA PET imaging where applicable, and assessment of inter-reader and intra-reader agreement. Safety and tolerability will also be evaluated.

About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for more than 70 years. For more information, visit www.lantheus.com.

Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “can,” “continue,” “could,” “future,” “potential,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) the timing and potential outcomes of clinical studies, including SPARROW, evaluating the use of LNTH-2401 for the detection and characterization of prostate cancer; (ii) our ability to develop LNTH-2401 as a PET imaging agent; and (iii) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com

¹Gastrin-Releasing Peptide Receptor (GRPR) as a Novel Biomarker and Therapeutic Target in Prostate Cancer. National Library of Medicine. Published March 5, 2024. Accessed September 10, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC10916925/

FRISCO, TX, Sept. 28, 2026 (GLOBE NEWSWIRE) — Comstock Resources, Inc. (NYSE and NYSE Texas: CRK) (“Comstock” or the “Company”) announced today that in conjunction with the Azerbaijan International Investment Forum, Comstock and SOCAR entered into a Framework Agreement memorializing the previously announced strategic partnership and SOCAR’s $1.65 billion investment in the Haynesville Shale, North America’s premier natural gas basin with close proximity to the Gulf of America’s LNG export facilities. The Framework Agreement memorializes both parties’ mutual commitment to negotiate and execute a definitive purchase and sale agreement consistent with the previously announced letter of intent related to the $1.65 billion strategic partnership. The definitive purchase and sale agreement is anticipated to be signed no later than October 31, 2026, and the transaction is expected to be closed by the end of 2026.  

To maximize the value of the Haynesville shale assets, Comstock and SOCAR will work together to explore opportunities for SOCAR to market natural gas produced from the Haynesville Shale assets attributable to Comstock’s interest for sale as LNG in international markets outside the United States. The parties will be focused on identifying potential offtake counterparties, evaluating pricing structures and assessing logistical and regulatory considerations associated with such international marketing arrangements.

The strategic partnership is part of a broader relationship between the United States and Azerbaijan under the protocol of the 1^st Azerbaijan-United States Economic Dialogue that was signed in June 2026. The Azerbaijan-United States Framework for Securing of Supply in the Mining and Processing of Critical Minerals and Rare Earths was signed by the Azerbaijan Minister of Economy and the U.S. Assistant Secretary of State for Economic, Energy and Business Affairs. The agreement highlights that the United States and Azerbaijan have a long history of cooperation in the oil and gas sector and share a commitment to affordable, abundant energy.

About Comstock Resources

Comstock Resources, Inc. is a leading independent natural gas producer with operations focused on the development of the Haynesville shale in North Louisiana and East Texas. The Company’s stock is traded on the NYSE and the NYSE Texas under the symbol CRK.

About SOCAR

SOCAR is a global integrated energy company headquartered in Azerbaijan. The company operates across the energy value chain, from oil and gas exploration and production to refining, petrochemicals, transportation, trading, and distribution. With a broad international footprint, SOCAR contributes to the energy security of Azerbaijan and its strategic partners while advancing sustainable development.

Forward-Looking Statements

This press release may contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the expected execution of a definitive agreement, the expected timing and completion of the proposed transaction, the receipt of required regulatory approvals, the anticipated use of proceeds, expected leverage and interest savings and future development plans. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described herein, including the risk that a definitive agreement is not executed, that required approvals are not obtained or are delayed, or that the transaction is not completed on the terms described or at all. Although the Company believes the expectations in such statements to be reasonable, there can be no assurance that such expectations will prove to be correct. Information concerning the assumptions, uncertainties and risks that may affect the actual results can be found in the Company’s filings with the Securities and Exchange Commission (“SEC”) available on the Company’s website or the SEC’s website at sec.gov.

Ron Mills
Vice President of Finance and Investor Relations
Comstock Resources
972-668-8834
rmills@comstockresources.com

CONTACT: Ron Mills
VP - Finance and Investor Relations
Comstock Resources
972-668-8834
rmills@comstockresources.com

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.

“We are delighted to welcome two distinguished commercialization and life science leaders to the Humacyte Board as we continue to expand our ongoing Symvess^® launch and prepare for our planned commercial launch of the ATEV in the dialysis access indication,” said Dr. Laura Niklason, Founder, President, and Chief Executive Officer of Humacyte. “Scott Coward brings a track record of success through his leadership at Exact Sciences and has significant experience in board service and executive leadership within publicly traded life sciences companies. Paul Kuznik has extensive experience in vascular healthcare and cardiovascular devices, including extensive leadership roles in commercialization, enterprise leadership, manufacturing, strategic planning, and physician engagement. We look forward to their contributions as we work toward our anticipated U.S. market launch in dialysis.”

Scott Coward served as Executive Vice President, Chief Legal Officer, Chief Administrative Officer and Secretary of Exact Sciences Corporation from January 2015 to December 2022. Mr. Coward led the integration of Genomic Health Corp. following its acquisition by Exact Sciences. He also served on the Exact Sciences board of directors from December 2022 to March 2026. Mr. Coward has been an attorney at K&L Gates since July 2026 and was previously a partner in the firm from 2008 through 2014. During that tenure, he served in different leadership roles, including as the managing partner of the Raleigh office. Mr. Coward brings significant experience in public company board service and corporate governance, executive leadership within publicly traded life sciences companies, mergers and acquisitions and post-acquisition integration, executive compensation, compliance and legal affairs, organizational leadership during periods of substantial growth and change, and has partnered with executive management teams and boards through transformational corporate events. Mr. Coward received his J.D. from Columbia Law School and his B.S. from the University of North Carolina at Chapel Hill. He has been appointed to the Company’s Audit Committee.

“I am honored to join the Humacyte Board of Directors at such an exciting time for the Company,” said Mr. Coward. “Humacyte’s pioneering work in regenerative medicine has the potential to transform patient care, and I look forward to working with the Board and management team to support the Company’s continued growth and long-term success.”

Paul Kuznik is a medical technology executive whose career spans more than three decades in vascular healthcare, cardiovascular devices, and medical diagnostics. Mr. Kuznik served as the Chief Executive Officer and a member of the Board of Directors from 2015 to 2018 at Bolton Medical, a developer of endovascular technologies for complex aortic disease, which was acquired by Terumo Corporation. Following the acquisition, Mr. Kuznik remained with Terumo Corporation, one of Japan’s leading global medical technology companies. He helped lead the integration of Bolton Medical with Vascutek to create Terumo Aortic and subsequently served as President of Terumo Aortic United States from 2019 to 2020 and as President of Terumo Aortic North America from 2020 to 2023. Mr. Kuznik brings extensive experience in commercialization, enterprise leadership, organizational integration, strategic planning, manufacturing, clinical affairs, regulatory oversight, quality systems, physician engagement and board governance. Mr. Kuznik is a graduate of the United States Military Academy at West Point and served as an officer in the United States Army. He has been appointed to the Company’s Commercial Committee.

“I’m thrilled to join the Board of Directors at Humacyte as the Company’s regenerative medicine technologies have the potential to make a significant impact across numerous markets while benefiting patients throughout the world,” said Mr. Kuznik. “I’m excited to work with the Board of Directors and Humacyte in our efforts to expand both physician and patient access to the innovative regenerative vascular solutions offered by the Company.”

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/debe51f6-5e18-4813-9829-d8e85bd71f10
https://www.globenewswire.com/NewsRoom/AttachmentNg/4e6163ac-4843-48ad-b0bb-76203e9bda00